IMRX
NASDAQ · Biotechnology
Immuneering Corp - Class A
$5.22
+0.00 (+0.00%)
Open$5.22
Previous Close$5.22
Day High$5.26
Day Low$5.11
52W High$10.08
52W Low$1.10
Volume—
Avg Volume772.9K
Market Cap337.49M
P/E Ratio—
EPS$-1.38
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
-32.2% upside
Current
$5.22
$5.22
Target
$3.54
$3.54
$2.50
$3.54 avg
$3.55
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 183.49M | 183.65M | 175.87M |
| Net Income | 12.93M | 12.84M | 10.17M |
| Profit Margin | 7.1% | 7.0% | 5.8% |
| EBITDA | 22.71M | 20.96M | 19.85M |
| Free Cash Flow | 10.88M | 9.00M | 9.93M |
| Rev Growth | -6.7% | +18.5% | +10.5% |
| Debt/Equity | 0.36 | 0.44 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |